EFFECT OF DIABETES MELLITUS ON RIFAMPICIN PEAK SERUM CONCENTRATION
DOI:
https://doi.org/10.22159/ijpps.2016v8i10.13238Keywords:
Rifampicin, Cmax, Diabetes mellitus, Pulmonary tuberculosis, Diabetes and tuberculosis, DM and TBAbstract
Objective: To comparatively analyze the peak serum concentration (Cmax) of rifampicin and to determine the incidence of decreased Cmax between diabetic and non-diabetic adult pulmonary tuberculosis patients.
Methods: A cross-sectional observational study was carried out in the chest and tuberculosis (TB) department of a tertiary care hospital after the approval of the institutional ethics committee. Five millilitre (ml) of blood was withdrawn by venipuncture from each patient at a time point of 2 h post dose administration at steady state concentration (Css). The separated serum was centrifuged at a rate of 3500 rotations per minute (rpm) for a period of fifteen minutes and the resultant serum was stored at-70 ° C until analysis. Estimation of rifampicin concentration was carried out in Thermo TSQ Ultra (MS/MS) with Shimadzu 20 AD UFLC LC-MS.
Results: The mean (Standard Deviation (SD)) age of the study population was 46.8 (14.2) years. The mean serum Cmax of rifampicin was significantly less in diabetic patients with pulmonary tuberculosis (p=0.0305). Statistically, a significant difference in the incidence of a decrease in Cmax was found between diabetic and non-diabetic patients (p=0.0335). Diabetes mellitus was found to be the predominant factor that affects rifampicin Cmax.
Conclusion: In this study, an effect of diabetes mellitus (DM) on the peak serum concentration of rifampicin was observed. Patients with hyperglycemia levels had significantly reduced levels of rifampicin serum concentrations, thus showing an inversely proportional relationship between blood glucose and rifampicin serum levels.
Downloads
References
Fogel N. Tuberculosis: a disease without boundaries. Tuberculosis 2015;95:527-31.
Niazi AK, Kalra S. Diabetes and tuberculosis: a review of the role of optimal glycemic control. J Diabetes Metab Disord 2012;11:1-4.
TB Facts. TB, tests, drugs, statistics [Internet]. TB Facts. Org; 2016. Available from: http://www.tbfacts.org/. [Last accessed on 18 Apr 2016].
Preethi S, Pradeep K, Rachna S, Vijaykumar A. Futuristic scope of biomarkers in tuberculosis. Asian J Pharm Clin Res 2015;8:34-6.
Sutrisna EM. Autoinduction properties of rifampicin on Javanese tuberculosis with variant type CYP3A4*1G. Asian J Pharm Clin Res 2015;8:21-3.
Tuberculosis [Internet]. World Health Organization; 2016. Available from: http://www.who.int/mediacentre/ factsheets/ fs104/en/. [Last accessed on 18 Apr 2016].
TB India 2015 Revised National TB Control Programme Annual Status Report, New Delhi; 2015. Available from: www.tbcindia.nic.in. [Last accessed on 18 Apr 2016].
Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P, et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis 2013;13:436-48.
Morton R. Phthisiolgia: or a treatise of consumptions. London: Smith and Walford; 1694. p. 28.
WHO Annual Report. Tuberculosis control in South-East-Asia Region ISBN 978-92-9022-476-1 (NLM classification: WU 30); 2010.
PV Rao. Persons with type 2 diabetes and comorbid active tuberculosis should be treated with insulin. Int J Diabetes 1999;19:1-4.
Nijiland H, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RHH, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. CID 2006;43:848-54.
Srivastava A, Waterhouse D, Ardrey A, Ward SA. Quantification of rifampicin in human plasma and cerebrospinal fluid by a highly sensitive and rapid liquid chromatographic–tandem mass spectrometric method. J Pharm Biomed Anal 2012;70:523–8.
Mendez AR, Davies G, Ardrey A, Jave O, Romero SL, Ward SA, et al. Pharmacokinetics of rifampicin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob Agents Chemother 2012;56:2357-63.
Ruslami R, Nijiland HMJ, Adhiarta GN, Kariadi HKS, Alisjahbana B. Pharmacokinetics of anti-tuberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother 2010;5:1068–74.
Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerging Infectious Diseases 2010;16:1546-53.
Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER. Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA. Tuberculosis Res Treatment 2013;23:1-6.
Published
How to Cite
Issue
Section
